Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Nanomaterial based enrichment of blood proteins for cancer detection and monitoring

EF 2013-14

Résumé
2 in 5 Canadians will develop cancer in their lifetime and about 1 in 4 Canadians will die of cancer. For the next 25 years, the monetary impact of cancer is estimated at $543 billion. Early detection and timely monitoring of cancer is critical for improving patient survival, preventing tumour spread and personalizing therapy. The protein profile of blood in cancer patients is unique and this has formed the basis of biomarker discovery. These differences and changes are minute and heterogeneous but have diagnostic potential. Current biomarker blood tests cannot detect cancer at an early stage and have false positive complications. The dream for single biomarker has not been fulfilled because cancer is a manifestation of dynamic and multiple genetic mutations. Thus, there is a major need to develop a selective, non-perturbing, cost-effective, time sensitive and easy to use diagnostic platform that can take advantage of this unique protein signature to detect, monitor and guide therapy. Nanomaterials, structures with dimensions in the range of 1-100 nm, offer a unique opportunity to address the above need due to their size and large surface area. When a nanomaterial comes in contact with blood, the protein layer that adsorbs on its surface is called protein 'corona'. This corona is, in essence, the biological identity of the nanomaterial and is dependent on its synthetic identity. Further, nanomaterials can be engineered (physical & chemical properties) to selectively extract proteins from blood. As our studies show, this can provide an avenue for enrichment of low abundance proteins from blood onto a nanomaterial surface. Using patient samples, we propose to design nanomaterials to selectively capture and enrich proteins that will enable identification of cancer type and stage. Our platform technology's ability to reflect and unlock protein differences occurring in physiological and pathological states can potentially revolutionize diagnostics and monitoring.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
299939
Name
Sindhwani Shrey
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Nanomaterial based enrichment of blood proteins for cancer detection and monitoring
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Cancer; Diagnostics; Mass Spectroscopy; Nanomaterial; Nanomedicine; Nanoparticle; Protein Corona; Proteomics
Abstract
2 in 5 Canadians will develop cancer in their lifetime and about 1 in 4 Canadians will die of cancer. For the next 25 years, the monetary impact of cancer is estimated at $543 billion. Early detection and timely monitoring of cancer is critical for improving patient survival, preventing tumour spread and personalizing therapy. The protein profile of blood in cancer patients is unique and this has formed the basis of biomarker discovery. These differences and changes are minute and heterogeneous but have diagnostic potential. Current biomarker blood tests cannot detect cancer at an early stage and have false positive complications. The dream for single biomarker has not been fulfilled because cancer is a manifestation of dynamic and multiple genetic mutations. Thus, there is a major need to develop a selective, non-perturbing, cost-effective, time sensitive and easy to use diagnostic platform that can take advantage of this unique protein signature to detect, monitor and guide therapy. Nanomaterials, structures with dimensions in the range of 1-100 nm, offer a unique opportunity to address the above need due to their size and large surface area. When a nanomaterial comes in contact with blood, the protein layer that adsorbs on its surface is called protein 'corona'. This corona is, in essence, the biological identity of the nanomaterial and is dependent on its synthetic identity. Further, nanomaterials can be engineered (physical & chemical properties) to selectively extract proteins from blood. As our studies show, this can provide an avenue for enrichment of low abundance proteins from blood onto a nanomaterial surface. Using patient samples, we propose to design nanomaterials to selectively capture and enrich proteins that will enable identification of cancer type and stage. Our platform technology's ability to reflect and unlock protein differences occurring in physiological and pathological states can potentially revolutionize diagnostics and monitoring.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Sindhwani, Shrey
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~